Jon Faiz Kayyem - 31 May 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Role
Director
Signature
/s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem
Issuer symbol
INBX
Transactions as of
31 May 2024
Net transactions value
+$4,927,580
Form type
4
Filing time
04 Jun 2024, 17:27:32 UTC
Previous filing
30 May 2024
Next filing
07 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INBX Common Stock Purchase $1,132,915 +70,193 +8.7% $16.14* 876,268 31 May 2024 By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust F1
transaction INBX Common Stock Purchase $777,215 +46,792 +5.3% $16.61* 923,060 03 Jun 2024 By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust F2
transaction INBX Common Stock Purchase $1,445,210 +80,738 +8.7% $17.90* 1,003,798 03 Jun 2024 By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust F3
transaction INBX Common Stock Purchase $1,139,477 +65,337 +6.5% $17.44* 1,069,135 04 Jun 2024 By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust F4
transaction INBX Common Stock Purchase $432,762 +23,726 +2.2% $18.24* 1,092,861 04 Jun 2024 By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were purchased in multiple transactions at prices ranging from $15.75 to $16.25, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2 The shares were purchased in multiple transactions at prices ranging from $16.25 to $16.75, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3 The shares were purchased in multiple transactions at prices ranging from $17.40 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F4 The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F5 The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.